Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

I. Suggested Operational Fix

No.ProponentTopicDeferred to Phase 2?FileTentative Presentation Date
1Kristine Dorrain

B. NOTICE

3. Other topics



2Maxim Alzoba

F. REMEDIES

2. Duration of Suspension Period

3. Review of Implementation



3Zak Muscovitch

F. REMEDIES

2. Duration of Suspension Period

3. Review of Implementation



4George Kirikos

F. REMEDIES

4. Other topics



II. Draft Policy Recommendation 

No.ProponentTopic (Mapped to the Super Consolidated URS Topics Table)Deferred to Phase 2?FileNotes
5George Kirikos

A. THE COMPLAINT

3. Limited filing period

Yes
6Claudio DiGangi

A. THE COMPLAINT

8. Other topics



7George Kirikos

B. NOTICE

1. Receipt by registrant (Notice - feedback from Complainant & Respondent)

Yes
8George Kirikos

C. RESPONSE

1. Duration of response period

Yes
9David McAuley

C. RESPONSE (primary topic)

1. Duration of response period

==

G. APPEAL (secondary topic)

2. De novo review



10Brian Winterfeldt; Christopher Thomas; Colin O’Brien; Griffin Barnett; Jeff Neuman; John McElwaine; Lori Schulman; Pascal Boehner; Paul McGrady; Susan Payne

C. RESPONSE (primary topic)

1. Duration of response period

==

G. APPEAL (secondary topic)

2. De novo review



11Brian Winterfeldt; Christopher Thomas; Colin O’Brien; Griffin Barnett; Jeff Neuman; John McElwaine; Lori Schulman; Pascal Boehner; Paul McGrady; Susan Payne

C. RESPONSE

3. Response fee



12George Kirikos

D. STANDARD OF PROOF

1. General

Yes
13Marie Pattullo (AIM - European Brands Association)

F. REMEDIES

1. Scope of remedies



14Marie Pattullo (AIM - European Brands Association)

F. REMEDIES

1. Scope of remedies



15Brian Winterfeldt; Christopher Thomas; Colin O’Brien; Griffin Barnett; Jeff Neuman; John McElwaine; Lori Schulman; Pascal Boehner; Paul McGrady; Susan Payne

F. REMEDIES

1. Scope of remedies



16Brian Winterfeldt; Christopher Thomas; Colin O’Brien; Griffin Barnett; Jeff Neuman; John McElwaine; Lori Schulman; Pascal Boehner; Paul McGrady; Susan Payne

F. REMEDIES

1. Scope of remedies

2. Duration of suspension period



17Marie Pattullo (AIM - European Brands Association)

F. REMEDIES

2. Duration of suspension period



18George Kirikos

G. APPEAL

1. Appeals process

Yes
19George Kirikos

G. APPEAL

1. Appeals process

Yes


20George Kirikos

G. APPEAL

1. Appeals process

Yes
21Marie Pattullo (AIM - European Brands Association)

I. COST

1. Cost allocation model



22Brian Winterfeldt; Christopher Thomas; Colin O’Brien; Griffin Barnett; Jeff Neuman; John McElwaine; Lori Schulman; Pascal Boehner; Paul McGrady; Susan Payne

I. COST

1. Cost allocation model



23George Kirikos

I. COST

1. Cost allocation model

Yes
24George Kirikos

J. LANGUAGE ISSUES

1. Language issues, including current requirements for complaint, notice of complaint, response, determination



25Zak Muscovitch

J. LANGUAGE ISSUES

1. Language issues, including current requirements for complaint, notice of complaint, response, determination



26Zak Muscovitch

M. URS PROVIERS

1. Evaluation of URS providers and their respective processes (including training of panelists)



27Zak Muscovitch

M. URS PROVIERS

1. Evaluation of URS providers and their respective processes (including training of panelists)



28Zak Muscovitch

M. URS PROVIERS

2. Conflict of interest



29George Kirikos

M. URS PROVIDERS

(no applicable subheading at present)



30George Kirikos

N. ALTERNATIVE PROCESSES

1. Possible alternative(s) to the URS, e.g. summary procedure in the UDRP

Yes
31David McAuley

(no applicable subheading at present)



III. Other 

No.ProponentTopicDeferred to Phase 2?
File
32George Kirikos

N. ALTERNATIVE PROCESSES

1. Possible alternative(s) to the URS, e.g., summary procedure in the UDRP



33George Kirikos(no applicable subheading at present)Yes